TTC7B

Summary

TTC7B (tetratricopeptide repeat domain 7B, HGNC:19858) is a protein-coding gene on chromosome 14q32.11, encoding Tetratricopeptide repeat protein 7B (Q86TV6). Component of a complex required to localize phosphatidylinositol 4-kinase (PI4K) to the plasma membrane.

Involved in phosphatidylinositol phosphate biosynthetic process and protein localization to plasma membrane. Located in cytosol and plasma membrane.

Source: NCBI Gene 145567 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 133 total
• MANE Select transcript: NM_001010854

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19858
Approved symbol	TTC7B
Name	tetratricopeptide repeat domain 7B
Location	14q32.11
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000165914
Ensembl biotype	protein_coding
OMIM	620060
Entrez	145567

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 12 protein_coding, 4 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 2 retained_intron

ENST00000328459, ENST00000553948, ENST00000553972, ENST00000554462, ENST00000554654, ENST00000555005, ENST00000555239, ENST00000555894, ENST00000556490, ENST00000556749, ENST00000556960, ENST00000557059, ENST00000557187, ENST00000557292, ENST00000557766, ENST00000919976, ENST00000919977, ENST00000963264, ENST00000963265, ENST00000963266

RefSeq mRNA: 3 — MANE Select: NM_001010854 NM_001010854, NM_001320421, NM_001401365

CCDS: CCDS32140

Canonical transcript exons

ENST00000328459 — 20 exons

Exon	Start	End
ENSE00000941125	90658304	90658387
ENSE00001214462	90676523	90676660
ENSE00001297705	90680472	90680535
ENSE00001298819	90695500	90695578
ENSE00001317652	90689540	90689712
ENSE00001388803	90744792	90744922
ENSE00001390457	90730075	90730196
ENSE00001434205	90524564	90541589
ENSE00002693320	90816175	90816430
ENSE00003477514	90786174	90786328
ENSE00003522180	90780738	90780906
ENSE00003522377	90657174	90657278
ENSE00003530818	90578106	90578308
ENSE00003549299	90617929	90618045
ENSE00003577596	90654993	90655110
ENSE00003586899	90593486	90593626
ENSE00003599048	90610742	90610839
ENSE00003678948	90646951	90647023
ENSE00003689939	90644048	90644208
ENSE00003788774	90652841	90652898

Expression profiles

Bgee: expression breadth ubiquitous, 245 present calls, max score 98.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.2648 / max 169.5902, expressed in 1682 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
144471	8.8044	1678
144472	0.4604	236

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	98.42	gold quality
cerebellar cortex	UBERON:0002129	98.26	gold quality
cerebellar hemisphere	UBERON:0002245	98.26	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.17	gold quality
cerebellum	UBERON:0002037	97.95	gold quality
prefrontal cortex	UBERON:0000451	97.51	gold quality
anterior cingulate cortex	UBERON:0009835	97.38	gold quality
right frontal lobe	UBERON:0002810	97.19	gold quality
cerebellar vermis	UBERON:0004720	96.91	gold quality
amygdala	UBERON:0001876	96.57	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.53	gold quality
frontal cortex	UBERON:0001870	96.24	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.13	gold quality
neocortex	UBERON:0001950	96.09	gold quality
nucleus accumbens	UBERON:0001882	95.63	gold quality
cerebral cortex	UBERON:0000956	95.27	gold quality
gastrocnemius	UBERON:0001388	95.16	gold quality
hypothalamus	UBERON:0001898	95.10	gold quality
caudate nucleus	UBERON:0001873	94.85	gold quality
putamen	UBERON:0001874	94.82	gold quality
muscle of leg	UBERON:0001383	94.78	gold quality
Ammon’s horn	UBERON:0001954	94.78	gold quality
brain	UBERON:0000955	94.68	gold quality
pons	UBERON:0000988	94.57	gold quality
forebrain	UBERON:0001890	94.37	gold quality
temporal lobe	UBERON:0001871	94.20	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.15	gold quality
ventricular zone	UBERON:0003053	94.09	gold quality
lower esophagus	UBERON:0013473	94.08	gold quality
lateral globus pallidus	UBERON:0002476	94.00	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7303	yes	23.43
E-ANND-3	yes	7.29
E-MTAB-6678	no	4.73

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

67 targeting TTC7B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-545-5P	99.66	70.18	2308

Literature-anchored findings (GeneRIF, showing 3)

• associated with IS risk in the Spanish and combined data sets. Multiple independent lines of evidence therefore support the role of TTC7B in stroke susceptibility (PMID:22453632)
• 14q32.11 microdeletion including CALM1, TTC7B, PSMC1, and RPS6KA5: A new potential cause of developmental and language delay in three unrelated patients. (PMID:33634591)
• TTC7B is a new prognostic biomarker in head and neck squamous cell carcinoma linked to immune infiltration and ferroptosis. (PMID:37990988)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ttc7b	ENSDARG00000061207
mus_musculus	Ttc7b	ENSMUSG00000033530
rattus_norvegicus	Ttc7b	ENSRNOG00000027300
caenorhabditis_elegans		WBGENE00021444

Paralogs (14): IFT88 (ENSG00000032742), TTC7A (ENSG00000068724), TMTC4 (ENSG00000125247), TMTC1 (ENSG00000133687), TMTC3 (ENSG00000139324), TTC6 (ENSG00000139865), BBS4 (ENSG00000140463), TTC13 (ENSG00000143643), OGT (ENSG00000147162), CFAP70 (ENSG00000156042), TTC8 (ENSG00000165533), TTC16 (ENSG00000167094), TMTC2 (ENSG00000179104), TTC34 (ENSG00000215912)

Protein

Protein identifiers

Tetratricopeptide repeat protein 7B — Q86TV6 (reviewed: Q86TV6)

Alternative names: Tetratricopeptide repeat protein 7-like-1

All UniProt accessions (9): A0A0C4DGK5, Q86TV6, G3V3E4, G3V3H1, H0YIZ4, H0YJP9, H0YJS2, H0YK02, Q6PIF1

UniProt curated annotations — full annotation on UniProt →

Function. Component of a complex required to localize phosphatidylinositol 4-kinase (PI4K) to the plasma membrane. The complex acts as a regulator of phosphatidylinositol 4-phosphate (PtdIns(4)P) synthesis. In the complex, plays a central role in bridging PI4KA to EFR3B and HYCC1, via direct interactions.

Subunit / interactions. Component of a phosphatidylinositol 4-kinase (PI4K) complex, composed of PI4KA, EFR3 (EFR3A or EFR3B), TTC7 (TTC7A or TTC7B) and HYCC (HYCC1 or HYCC2). Interacts with PI4KA, interaction is direct. Interacts with EFR3 (EFR3A or EFR3B), interaction is direct. Interacts with HYCC (HYCC1 or HYCC2), interaction is direct. Association with the PI4K complex is strongly reduced by TMEM150A.

Subcellular location. Cytoplasm. Cytosol. Cell membrane.

Isoforms (2)

UniProt ID	Names	Canonical?
Q86TV6-1	1	yes
Q86TV6-2	2

RefSeq proteins (3): NP_001010854, NP_001307350, NP_001388294 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR019734	TPR_rpt	Repeat
IPR045819	TTC7_N	Domain
IPR051722	Endocytosis_PI4K-reg_protein	Family

Pfam: PF12895, PF13181, PF13424, PF19440

UniProt features (65 total): helix 37, repeat 11, modified residue 9, turn 5, chain 1, splice variant 1, strand 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
5DSE	X-RAY DIFFRACTION	2.9
9B9G	ELECTRON MICROSCOPY	3.5
9OT6	ELECTRON MICROSCOPY	3.54
6BQ1	ELECTRON MICROSCOPY	3.6
9BAX	ELECTRON MICROSCOPY	3.65

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86TV6-F1	85.55	0.62

Antibody-complex structures (SAbDab): 1 — 9OT6

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 160, 202, 625, 629, 630, 673, 677, 678, 681

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 149 (showing top): GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, CACCAGC_MIR138, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, ATGTTAA_MIR302C, GOBP_PHOSPHOLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, ACATTCC_MIR1_MIR206, GOBP_GLYCEROLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, GOBP_LOCALIZATION_WITHIN_MEMBRANE

GO Biological Process (2): phosphatidylinositol phosphate biosynthetic process (GO:0046854), protein localization to plasma membrane (GO:0072659)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): cytosol (GO:0005829), plasma membrane (GO:0005886), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
glycerophospholipid biosynthetic process	1
protein localization to membrane	1
protein localization to cell periphery	1
binding	1
cytoplasm	1
membrane	1
cell periphery	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

766 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TTC7B	HYCC1	Q9BYI3	938
TTC7B	EFR3B	Q9Y2G0	875
TTC7B	TMEM150A	Q86TG1	666
TTC7B	EFR3A	Q14156	630
TTC7B	PI4KA	P42356	621
TTC7B	HYCC2	Q8IXS8	565
TTC7B	PI4KB	P78405	532
TTC7B	TMED6	Q8WW62	493
TTC7B	LARGE2	Q8N3Y3	476
TTC7B	TEX2	Q8IWB9	475
TTC7B	NCS1	P36610	472
TTC7B	COPZ2	Q9P299	468
TTC7B	SH3GLB2	Q9NR46	461
TTC7B	NKIRAS1	Q9NYS0	449
TTC7B	FAM181A	Q8N9Y4	443

IntAct

36 interactions, top by confidence:

A	B	Type	Score
TTC7B	HYCC1	psi-mi:“MI:0915”(physical association)	0.560
TTC7B	HYCC2	psi-mi:“MI:0915”(physical association)	0.560
TTC7B	COG6	psi-mi:“MI:0915”(physical association)	0.560
TTC7B	RAB3IL1	psi-mi:“MI:0915”(physical association)	0.560
TTC7B	RUSC1	psi-mi:“MI:0915”(physical association)	0.560
CD226	MEN1	psi-mi:“MI:0914”(association)	0.530
GPC1	SNAP23	psi-mi:“MI:0915”(physical association)	0.400
GPC1	GANAB	psi-mi:“MI:0915”(physical association)	0.400
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
RGS20	PGP	psi-mi:“MI:0914”(association)	0.350
PI4KA	EFR3A	psi-mi:“MI:0914”(association)	0.350
DGCR2	CCDC85C	psi-mi:“MI:0914”(association)	0.350
CENPM	DNM1L	psi-mi:“MI:0914”(association)	0.350
RGS20	KIF3B	psi-mi:“MI:0914”(association)	0.350
CIMIP5	PI4KA	psi-mi:“MI:0914”(association)	0.350
PI4KA	GCLM	psi-mi:“MI:0914”(association)	0.350
POU3F1	DUSP3	psi-mi:“MI:0914”(association)	0.350
CTDSPL	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270
KCNK3	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
TTC7B	HYCC2	psi-mi:“MI:0915”(physical association)	0.000
TTC7B	COG6	psi-mi:“MI:0915”(physical association)	0.000
TTC7B	HYCC1	psi-mi:“MI:0915”(physical association)	0.000
RAB3IL1	TTC7B	psi-mi:“MI:0915”(physical association)	0.000
TTC7B	RUSC1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (32): TTC7B (Proximity Label-MS), TTC7B (Affinity Capture-MS), TTC7B (Two-hybrid), TTC7B (Two-hybrid), TTC7B (Two-hybrid), TTC7B (Two-hybrid), RAB3IL1 (Two-hybrid), TTC7B (Affinity Capture-MS), TTC7B (Proximity Label-MS), TTC7B (Proximity Label-MS), TTC7B (Affinity Capture-MS), TTC7B (Affinity Capture-MS), TTC7B (Affinity Capture-MS), TTC7B (Affinity Capture-MS), TTC7B (Affinity Capture-MS)

ESM2 similar proteins: A1A5P5, A1L1K3, A7SUU7, B4JHK2, B4NKT1, E9Q6P5, F1QN74, P09913, P50748, Q0P5W1, Q14CX7, Q294E0, Q2KI89, Q32NR4, Q32PH0, Q3U0M1, Q4R6I5, Q4R6M4, Q5R629, Q5RE52, Q5U249, Q5ZKK3, Q60462, Q68F70, Q6AYP3, Q6PA97, Q6QI44, Q80VM3, Q86TV6, Q8BGB2, Q8BH74, Q8BTZ4, Q8BWZ3, Q8C0S4, Q8CIM8, Q8GZN1, Q8IYW2, Q8JGR7, Q8K368, Q8N3P4

Diamond homologs: E9Q6P5, Q86TV6, Q8BGB2, Q9ULT0, A1Z8E9, P39143, Q1JQ97, Q28G25, Q5CZ52, Q8C1Z7, Q96RK4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

133 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	116
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

5630 predictions. Top by Δscore:

Variant	Effect	Δscore
14:90530573:T:C	acceptor_gain	1.0000
14:90530573:T:TC	acceptor_gain	1.0000
14:90644044:TTA:T	donor_loss	1.0000
14:90644045:TACAT:T	donor_loss	1.0000
14:90644046:A:AC	donor_gain	1.0000
14:90644046:A:AG	donor_loss	1.0000
14:90644047:C:CG	donor_gain	1.0000
14:90644047:CA:C	donor_gain	1.0000
14:90644047:CAT:C	donor_gain	1.0000
14:90644047:CATG:C	donor_gain	1.0000
14:90644047:CATGA:C	donor_gain	1.0000
14:90644204:GGGAT:G	acceptor_gain	1.0000
14:90644205:GGAT:G	acceptor_gain	1.0000
14:90644205:GGATC:G	acceptor_gain	1.0000
14:90644206:GAT:G	acceptor_gain	1.0000
14:90644206:GATC:G	acceptor_gain	1.0000
14:90644207:AT:A	acceptor_gain	1.0000
14:90644207:ATC:A	acceptor_gain	1.0000
14:90644208:TC:T	acceptor_gain	1.0000
14:90644209:C:CC	acceptor_gain	1.0000
14:90644209:CTG:C	acceptor_gain	1.0000
14:90644210:T:A	acceptor_loss	1.0000
14:90644210:T:G	acceptor_gain	1.0000
14:90644212:G:GC	acceptor_gain	1.0000
14:90644213:T:TC	acceptor_gain	1.0000
14:90644214:T:C	acceptor_gain	1.0000
14:90644214:T:TC	acceptor_gain	1.0000
14:90644220:C:CT	acceptor_gain	1.0000
14:90655111:C:CC	acceptor_gain	1.0000
14:90657168:ACT:A	donor_loss	1.0000

AlphaMissense

5441 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:90644138:A:G	L554P	1.000
14:90655022:C:T	G477E	1.000
14:90655023:C:A	G477W	1.000
14:90655023:C:G	G477R	1.000
14:90655023:C:T	G477R	1.000
14:90658320:A:G	L407P	1.000
14:90676569:A:G	L369P	1.000
14:90680488:A:G	L333P	1.000
14:90689696:A:G	L265P	1.000
14:90695548:T:A	R243S	1.000
14:90695548:T:G	R243S	1.000
14:90695549:C:A	R243I	1.000
14:90695549:C:G	R243T	1.000
14:90816229:A:G	W23R	1.000
14:90816229:A:T	W23R	1.000
14:90541420:A:G	L827P	0.999
14:90541499:A:G	W801R	0.999
14:90541499:A:T	W801R	0.999
14:90578206:C:T	G737D	0.999
14:90578252:C:G	A722P	0.999
14:90593498:A:G	W699R	0.999
14:90593498:A:T	W699R	0.999
14:90617960:A:G	W613R	0.999
14:90617960:A:T	W613R	0.999
14:90617968:A:G	L610P	0.999
14:90644126:A:G	L558P	0.999
14:90644129:A:G	L557P	0.999
14:90644135:A:G	L555P	0.999
14:90644199:C:G	A534P	0.999
14:90646955:C:A	R529I	0.999

dbSNP variants (sampled 300 via entrez): RS1000008122 (14:90595038 T>C), RS1000011347 (14:90540727 T>C), RS1000011448 (14:90556214 T>C), RS1000030651 (14:90626372 C>T), RS1000065861 (14:90601396 A>C), RS1000071397 (14:90686398 C>T), RS1000071849 (14:90799588 C>G,T), RS1000071957 (14:90729776 G>A), RS1000078934 (14:90692965 A>T), RS1000083776 (14:90778698 G>A), RS1000085598 (14:90533944 C>A,T), RS1000088273 (14:90548399 G>A,T), RS1000094617 (14:90713943 A>T), RS1000095427 (14:90736150 C>A), RS1000100458 (14:90686019 A>G)

Disease associations

OMIM: gene MIM:620060 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001272_9	Cytomegalovirus antibody response	9.000000e-06
GCST002696_1	Anxiety disorder	6.000000e-06
GCST004097_2	Response to platinum-based neoadjuvant chemotherapy in cervical cancer	7.000000e-06
GCST004862_28	Itch intensity from mosquito bite adjusted by bite size	6.000000e-06
GCST005956_47	Waist-to-hip ratio adjusted for BMI	7.000000e-07
GCST005962_28	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	7.000000e-07
GCST007505_12	Nevus count or cutaneous melanoma	4.000000e-07
GCST007672_7	3-month functional outcome in ischaemic stroke (modified Rankin score)	3.000000e-06
GCST011768_11	Schizophrenia	6.000000e-09
GCST90026412_4	Severe autoimmune type 2 diabetes	4.000000e-06

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007943	response to platinum-based neoadjuvant chemotherapy
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004632	nevus count
EFO:0009603	stroke outcome severity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	6
bisphenol A	increases expression, increases methylation, affects cotreatment, decreases methylation, decreases expression	4
Aflatoxin B1	affects expression, affects methylation, decreases expression	4
methylmercuric chloride	affects cotreatment, increases expression	3
Cyclosporine	increases expression	3
Air Pollutants	increases abundance, increases expression, decreases expression	2
Rotenone	increases expression	2
Valproic Acid	increases expression, affects expression	2
Particulate Matter	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	increases methylation, affects cotreatment	1
2,4,6-tribromophenol	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sodium arsenite	increases expression	1
zinc chromate	decreases expression, increases abundance	1
aflatoxin B2	increases methylation	1
acetochlor	affects methylation, increases abundance	1
avobenzone	increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	increases expression	1
jinfukang	affects cotreatment, decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9V6	Ubigene HEK293 TTC7B KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.